1、Integrated Annual Report 2024Pioneering access for patientsIntegrated Annual Report 2024OverviewFinancial ReportESG DisclosuresBusiness ReportGovernance,Compensation&RiskTable of contents04Sandoz at a glance27ESG and impact15Generics19Our biosimilars pipelineSee our online summary report S 2024 by t

2、he numbers02 Chairmans letter03 Chief Executives statement04 Sandoz at a glance06 Our business model08 2024 in reviewBusiness Report10 Our Purpose in action13 Our strategy15 Trends&market generics17 Trends&market biosimilars19 Our biosimilars pipeline21 Operational review23 Regional review Europe24

3、Regional review North America26 Regional review International27 ESG and impactCorporate Governance Report44 Corporate Governance framework44 ESG Governance45 Group structure and shareholders47 Board of Directors53 Executive CommitteeCompensation Report63 Shareholder letter from the Chair of the Huma

4、n Capital&ESG Committee64 Executive Committee and Board compensation at a glance65 Executive Committee compensation75 Board of Directors compensation79 Compensation governance85 Audit report for the Compensation ReportRisk Management Report87 Risk management88 Risks89 Risks detailed view Financial R

5、eport93 Performance overview99 Consolidated financial statements of the Group152 Audit report for the consolidated financial statements of the Group154 Supplementary financial information161 Financial statements of Sandoz Group AG169 Audit report for the financial statements of Sandoz Group AGESG Di

6、sclosures 172 ESG reporting standards and assurance173 Double materiality assessment methodology175 ESG performance indicators and data179 Article 964b:Swiss Civil Code of Obligations Compliance index180 Task Force on Climate-related Financial Disclosures(TCFD)185 Limited assurance report on selecte